ArticleAmerican heart journal plus : cardiology research and practice2025
Circulating mitochondrial cell-free DNA levels are associated with the recurrence of atrial fibrillation after catheter ablation for atrial fibrillation.
Article in American heart journal plus : cardiology research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although catheter ablation, including pulmonary vein isolation, is the primary nonpharmacological therapy for atrial fibrillation (AF), atrial arrhythmia often recurs. Recent studies have linked circulating mitochondrial cell-free DNA (mt-cfDNA), a potential contributor to inflammatory disorders, with AF. In this study, we evaluated the relationship between plasma mt-cfDNA levels and AF recurrence after catheter ablation in patients with AF. Methods: Peripheral blood was obtained from 58 patients with AF (34 paroxysmal and 24 persistent AF) who underwent catheter ablation and from the control group (10 patients without AF). We extracted total cfDNA and mt-cfDNA from the patients. Results: The total cfDNA concentration and copy number of mt-cfDNA were significantly higher in patients with AF than in controls. During the 16-month follow-up after catheter ablation, AF recurred in 11 patients (19.0 %). In patients with AF, the copy number of mt-cfDNA before catheter ablation was higher in the recurrent group than in the non-recurrent group. However, total cfDNA concentrations did not differ significantly between patients with and without AF recurrence. The left atrial volume index (LAVI) was higher in patients with recurrent AF than in those without. Cox proportional hazards regression analysis showed that the mt-cfDNA copy number was significantly associated with AF recurrence after catheter ablation, independent of age, sex, body mass index, LAVI, and AF type. Conclusion: Elevated mt-cfDNA levels may be a sensitive predictor of AF recurrence after catheter ablation in patients with AF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.